TELA Bio (NASDAQ:TELA) Posts Earnings Results, Beats Estimates By $0.02 EPS

TELA Bio (NASDAQ:TELA) issued its quarterly earnings results on Tuesday. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.02, Zacks reports. TELA Bio had a negative net margin of 48.37% and a negative return on equity of 396.31%. The company had revenue of $20.87 million for the quarter, compared to the consensus estimate of $21.04 million.

Here are the key takeaways from TELA Bio’s conference call:

• Company completed a major commercial rebuild, expanding to roughly ~90 sales reps (40% hired in the last six months), new sales leadership, territory realignment and a redesigned 2026 compensation plan intended to drive deeper account penetration.
• Financial momentum: TELA delivered 16% revenue growth in 2025 with a record Q4 of $20.9M and strong unit growth (OviTex units +20% Q4, +22% FY), and guided to at least +8% revenue growth in 2026 with Q1 ~ $18.5M.
• Improving unit economics and balance sheet: gross margin rose to 68% for the year, LiquiFix revenue more than tripled year-over-year in Q4, and the company ended 2025 with $50.8M cash after refinancing debt and raising capital.
• Product and clinical progress: launched OviTex LTR (long-term resorbable), advanced the LiquiFix fixation product, enrolled first patients in the hiatal hernia ECHO trial, and promoted an experienced CMO to support surgeon engagement and evidence generation.
• Near-term execution risks remain: guidance is deliberately conservative due to large cohorts of new reps still ramping, mixed-product ASP pressure from shifting procedure mix, contract conversion complexity, territory restructures and Q1 seasonality/weather disruptions that could pressure short-term results.

TELA Bio Trading Down 9.4%

NASDAQ:TELA opened at $0.69 on Thursday. The firm has a 50-day simple moving average of $0.85 and a 200-day simple moving average of $1.14. TELA Bio has a one year low of $0.62 and a one year high of $2.20. The firm has a market cap of $27.84 million, a P/E ratio of -0.83 and a beta of 0.88. The company has a debt-to-equity ratio of 26.65, a quick ratio of 2.62 and a current ratio of 3.30.

Key Headlines Impacting TELA Bio

Here are the key news stories impacting TELA Bio this week:

• Positive Sentiment: Management reported record quarterly sales and double‑digit revenue growth in Q4 2025 and described the period as a “meaningful strategic change” while targeting at least 8% revenue growth in 2026, supporting a constructive longer‑term commercial outlook. GlobeNewswire: Q4 and FY2025 Results
• Positive Sentiment: Reported EPS was slightly better than consensus (loss of $0.16 vs. consensus ~$0.18) and improved versus the prior year, which may temper downside for some investors. Zacks: TELA Q4 Results
• Neutral Sentiment: Management is executing a U.S. commercial organization rebuild — a transition that could improve sales execution longer‑term but may create near‑term execution risk and added expense. DefenseWorld: Q4 Earnings Highlights
• Neutral Sentiment: The company reiterated growth objectives (targeting at least ~8% revenue growth in 2026), which gives a directional target for revenue but not detailed margin or profitability milestones. Seeking Alpha: 2026 Revenue Target
• Negative Sentiment: Several analysts cut price targets after the report — Canaccord lowered its PT from $4 to $2 (maintaining a buy), Lake Street cut $3→$2 (buy), and Piper Sandler trimmed $1.25→$1.00 (neutral) — putting downward pressure on sentiment and the stock. AmericanBankingNews: Canaccord Lowers PT
• Negative Sentiment: Revenue slightly missed consensus ($20.87M reported vs. ~$21.04M expected) and several outlets note analysts trimmed forecasts after the print, reinforcing shorter‑term analyst caution. Benzinga: Analysts Cut Forecasts
• Negative Sentiment: TELA remains loss‑making with negative net margins and very negative return on equity, leaving profitability and cash‑flow improvement as material risks that keep upside dependent on execution. MarketBeat: Earnings Summary

Wall Street Analyst Weigh In

Several research analysts have issued reports on TELA shares. Lake Street Capital dropped their target price on TELA Bio from $3.00 to $2.00 and set a “buy” rating for the company in a research report on Wednesday. Canaccord Genuity Group decreased their price objective on shares of TELA Bio from $4.00 to $2.00 and set a “buy” rating for the company in a report on Wednesday. Loop Capital set a $3.00 target price on shares of TELA Bio in a research report on Monday, December 1st. Piper Sandler decreased their price target on shares of TELA Bio from $1.25 to $1.00 and set a “neutral” rating for the company in a research note on Wednesday. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of TELA Bio in a report on Thursday, January 22nd. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $2.60.

Hedge Funds Weigh In On TELA Bio

A number of large investors have recently bought and sold shares of TELA. XTX Topco Ltd purchased a new stake in TELA Bio during the fourth quarter worth $48,000. Renaissance Technologies LLC increased its holdings in shares of TELA Bio by 101.4% in the 4th quarter. Renaissance Technologies LLC now owns 128,700 shares of the company’s stock valued at $152,000 after acquiring an additional 64,800 shares during the period. Susquehanna International Group LLP raised its position in shares of TELA Bio by 551.2% in the 3rd quarter. Susquehanna International Group LLP now owns 85,763 shares of the company’s stock worth $128,000 after acquiring an additional 72,594 shares in the last quarter. Finally, Citadel Advisors LLC raised its position in shares of TELA Bio by 161.3% in the 3rd quarter. Citadel Advisors LLC now owns 35,281 shares of the company’s stock worth $53,000 after acquiring an additional 21,781 shares in the last quarter. Institutional investors own 94.35% of the company’s stock.

About TELA Bio

TELA Bio, Inc (NASDAQ: TELA) is a commercial‐stage medical technology company headquartered in Malvern, Pennsylvania. The company is focused on developing, manufacturing and commercializing regenerative medicine and advanced soft tissue repair solutions. By integrating proprietary biomaterials and processing technologies, TELA Bio aims to offer products that support the body’s natural healing processes in wound closure, hernia repair, reconstructive surgery and other surgical specialties.

The company’s product portfolio includes acellular dermal matrices, hemostatic agents and tissue scaffold systems.